Product Description.:
B, 50
tablet , film-coated , pink , round round
b within a heartDebossedBiconvex
ZIAC?
(bisoprolol fumarate and hydrochlorothiazide) Tablets
DRUG DESCRIPTION
ZIAC (bisoprolol fumarate and hydrochlorothiazide) is indicated for the treatment of hypertension. It combines two antihypertensive agents in a once-daily dosage: a synthetic beta1-selective (cardioselective) adrenoceptor blocking agent (bisoprolol fumarate) and a benzothiadiazine diuretic (hydrochlorothiazide).
Each ZIAC?-2.5 mg/6.25 mg tablet for oral administration contains:
Bisoprolol fumarate...................................................2.5 mg
Hydrochlorothiazide.................................................6.25 mg
Each ZIAC?-5 mg/6.25 mg tablet for oral administration contains:
Bisoprolol fumarate...................................................5 mg
Hydrochlorothiazide................................................. 6.25 mg
Each ZIAC?-10 mg/6.25 mg tablet for oral administration contains:
Bisoprolol fumarate..................................................10 mg
Hydrochlorothiazide.................................................6.25 mg
Inactive ingredients include Colloidal Silicon Dioxide, Corn Starch, Dibasic Calcium Phosphate, Hypromellose, Magnesium Stearate, Microcrystalline Cellulose, Polyethylene Glycol, Polysorbate 80, and Titanium Dioxide. The 5 mg/6.25 mg tablet also contains Red and Yellow Iron Oxide. The 2.5 mg/6.25 mg tablet also contains Crospovidone, Pregelatinized Starch, and Yellow Iron Oxide.
INDICATIONS
ZIAC (bisoprolol fumarate and hydrochlorothiazide) is indicated in the management of hypertension.
SIDE EFFECTS
ZIAC
Bisoprolol fumarate/H6.25 mg is well tolerated in most patients. Most adverse effects (AEs) have been mild and transient. In more than 65,000 patients treated worldwide with bisoprolol fumarate, occurrences of bronchospasm have been rare. Discontinuation rates for AEs were similar for B/H6.25 mg and placebo-treated patients.
